Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Marina Cazzaniga , Claudio Verusio , Mariangela Ciccarese , Alberto Fumagalli , Donata Sartori , Maria Rosaria Valerio , Mario Airoldi , Gabriella Moretti , Corrado Ficorella , Valentina Arcangeli , Lucrezia Diodati , Alberto Zambelli , Antonio Febbraro , Daniele Generali , Mirco Pistelli , Ornella Garrone , Antonino Musolino , Patrizia Vici , Michela Maur , Lucia Mentuccia , Nicla La Verde , Giulia Bianchi , Salvatore Artale , Livio Blasi , Matilde Piezzo , Francesco Atzori , Anna Turletti , Chiara Benedetto , Maria Concetta Cursano , Alessandra Fabi , Vittorio Gebbia , Alessio Schirone , Raffaella Palumbo , Antonella Ferzi , Antonio Frassoldati , Claudio Scavelli , Luca Clivio , Valter Torri On Behalf Of The Eva Study Group Oncotarget（2018）
Abstract
[This corrects the article DOI: 10.18632/oncotarget.25874.].
More Translated text
Key words
advanced breast cancer, elderly, everolimus, exemestane, hormone-receptor positive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
